3rd Edition of International Cancer & Immuno-Oncology Conference
March 15-17, 2027 | Singapore
Basal Cell Carcinoma
Basal cell carcinoma (BCC) is the most common form of skin cancer, often caused by prolonged exposure to ultraviolet (UV) radiation from the sun. In Cancer Research, understanding the genetic mutations driving BCC has led to targeted therapies like hedgehog pathway inhibitors. These drugs disrupt the signaling pathway implicated in BCC development, offering promising outcomes for patients with advanced or metastatic BCC. Moreover, research into immunotherapies for BCC is gaining traction, harnessing the body's immune system to recognize and destroy cancer cells. Despite advancements, prevention remains crucial, emphasizing sun protection measures and regular skin screenings. Continued research endeavors aim to enhance treatment efficacy, minimize side effects, and ultimately improve the prognosis for individuals affected by basal cell carcinoma.
Rajvir Dahiya
University of California San Francisco, United States
Thomas Jay Webster
Brown University, United States
Yan Leyfman
NYP- Meyer Cancer Center, United StatesSubmit your abstract Today
Title : Nanomedicine in over 45,000 patients and no cancer
Thomas Jay Webster, Brown University, United States